EC approves  subcutaneous route of administration in Sandoz biosimilar, Binocrit

EC approves subcutaneous route of administration in Sandoz biosimilar, Binocrit

novartis_logo
Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in its drug Binocrit (epoetin alfa), a prescription medicine that stimulates the bone marrow to produce red blood cells (anemia in either the nephrology or oncology setting).
“By expanding our biosimilar offering to the healthcare community, the EC approval of a subcutaneous route of administration for use in our Binocrit’s nephrology indication will mean more choice for healthcare professionals as well as increased convenience for patients” said Carol Lynch, Global Head Biopharmaceuticals, Sandoz.
The EU approval was based on data from the SENSE clinical study – an open label, single arm, multicenter study to evaluate the safety and immunogenicity of HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in pre-dialysis and dialysis patients.
The company says it is committed to increasing patient access to high-quality, life-enhancing biosimilars

About author

You might also like

PHARMA NEWS 0 Comments

U.S. appeals court dismisses case over alleged suicide link with GSK’s antidepressant

A U.S. appeals court on Wednesday tossed a $3 million verdict against GlaxoSmithKline over the suicide of an attorney who took a generic version of the company’s antidepressant Paxil (named

PHARMA NEWS 0 Comments

Merck, Pfizer, Syndax Collaborate to evaluate combination drug for ovarian cancer

Multinational pharmaceutical companies, Merck, Pfizer and Syndax Pharmaceuticals, Inc. have entered into a collaboration agreement to evaluate avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Syndax’s

Novartis launches SMS for Life 2.0 to help improve access to essential medicines

Novartis announced today the launch of an innovative technology-based healthcare program called SMS for Life 2.0 in Kaduna State, Nigeria. The program aims to increase the availability of essential medicines

0 Comments

No Comments Yet!

You can be first to comment this post!

Leave a Reply